GSK-3-mediated regulation of cellular functions and signaling pathways
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20263802Keywords:
Glycogen synthase kinase-3, GSK-3α, GSK-3β, Cellular signaling, Cellular homeostasis, NeurodegenerationAbstract
Glycogen synthase kinase-3 (GSK-3) is a highly conserved serine/threonine kinase that has emerged as a central regulator of diverse cellular signaling networks and physiological processes. Originally recognized for its role in glycogen metabolism, GSK-3 is now known to participate in the regulation of gene expression, metabolism, proliferation, differentiation, development, apoptosis, cellular adhesion, migration, and neuronal function. Its activity is controlled through multiple regulatory mechanisms, including inhibitory phosphorylation and modulation of protein complexes, enabling GSK-3 to respond dynamically to extracellular and intracellular signals. The two paralogues, GSK-3α and GSK-3β, share considerable structural similarity but may exhibit distinct and sometimes overlapping biological functions. Dysregulated GSK-3 signaling has been associated with neurological and neurodegenerative disorders, metabolic and inflammatory diseases, and cancer. Although pharmacological inhibition of GSK-3 has therefore attracted considerable therapeutic interest, clinical translation remains challenging because of limited isoform selectivity, context-dependent biological effects, and the complex physiological functions of this kinase. Recent findings further demonstrate that GSK-3 can regulate central cellular processes through distinct isoform-dependent mechanisms, emphasizing the importance of understanding its spatial, temporal, and substrate-specific regulation. A comprehensive characterization of GSK-3α and GSK-3β may consequently facilitate the development of more selective and clinically effective therapeutic strategies.
References
Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle: separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 1980;107(2):519–27.
Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990;9(8):2431–8.
Sutherland C. What are the bona fide GSK3 substrates? Int J Alzheimers Dis. 2011;2011:505607.
McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, et al. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. 2017;8(8):14221–50.
Patel P, Woodgett JR. Glycogen synthase kinase 3: a kinase for all pathways? In: Current Topics in Developmental Biology. Vol. 123. Academic Press; 2017. p. 277–302.
Hoffmeister L, Diekmann M, Brand K, Huber R. GSK3: a kinase balancing promotion and resolution of inflammation. Cells. 2020;9(4):820.
Albrecht LV, Tejeda-Muñoz N, De Robertis EM. Cell biology of canonical Wnt signaling. Annu Rev Cell Dev Biol. 2021;37:369–89.
Li C, Furth EE, Rustgi AK, Klein PS. When you come to a fork in the road, take it: Wnt signaling activates multiple pathways through the APC/Axin/GSK-3 complex. Cells. 2023;12(18):2256.
Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114–31.
Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, et al. Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018;10(431):eaam8460.
Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL, et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3β inactivation. Science. 2008;320(5876):667–70.
Jope RS, Cheng Y, Lowell JA, Worthen RJ, Sitbon YH, Beurel E. Stressed and inflamed, can GSK3 be blamed? Trends Biochem Sci. 2017;42(3):180–92.
Calvo B, Fernandez M, Rincon M, Tranque P. GSK3β inhibition by phosphorylation at Ser389 controls neuroinflammation. Int J Mol Sci. 2023;24(1):337.
Calvo B, Thornton TM, Rincon M, Tranque P, Fernandez M. Regulation of GSK3β by Ser389 phosphorylation during neural development. Mol Neurobiol. 2021;58(2):809–20.
Skrzypczak-Wiercioch A, Sałat K. Lipopolysaccharide-induced model of neuroinflammation: mechanisms of action, research application and future directions for its use. Molecules. 2022;27(17):5481.
Jiang H, Li L, Zhang L, Zang G, Sun Z, Wang Z. Role of endothelial cells in vascular calcification. Front Cardiovasc Med. 2022;9:895005.
Cai X, Zhao Y, Yang Y, Wu X, Zhang L, Ma JA, et al. GSK3β inhibition ameliorates atherosclerotic calcification. Int J Mol Sci. 2023;24(14):11638.
Boström KI, Qiao X, Zhao Y, Wu X, Zhang L, Ma JA, et al. GSK3β inhibition reduced vascular calcification in Ins2Akita/+ mice. Int J Mol Sci. 2023;24(6):5971.
Mastrogiacomo L, Werstuck GH. Investigating the role of endothelial glycogen synthase kinase 3α/β in atherogenesis in low-density lipoprotein receptor knockout mice. Int J Mol Sci. 2022;23(23):14780.
Sag CM, Schnelle M, Zhang J, Murdoch CE, Kossmann S, Protti A, et al. Distinct regulatory effects of myeloid cell and endothelial cell NADPH oxidase 2 on blood pressure. Circulation. 2017;135(22):2163–77.
Banko NS, McAlpine CS, Venegas-Pino DE, Raja P, Shi Y, Khan MI, et al. Glycogen synthase kinase 3α deficiency attenuates atherosclerosis and hepatic steatosis in high-fat diet-fed low-density lipoprotein receptor-deficient mice. Am J Pathol. 2014;184(12):3394–404.
McAlpine CS, Huang A, Emdin A, Banko NS, Beriault DR, Shi Y, et al. Deletion of myeloid GSK3α attenuates atherosclerosis and promotes an M2 macrophage phenotype. Arterioscler Thromb Vasc Biol. 2015;35(5):1113–22.
Shenker BJ, Walker LP, Zekavat A, Korostoff J, Boesze-Battaglia K. Aggregatibacter actinomycetemcomitans cytolethal distending toxin induces cell cycle arrest in a glycogen synthase kinase (GSK)-3-dependent manner in oral keratinocytes. Int J Mol Sci. 2022;23(19):11831.
Loxha L, Ibrahim NK, Stasche AS, Cinar B, Dolgner T, Niessen J, et al. GSK3α regulates temporally dynamic changes in ribosomal proteins upon amino acid starvation in cancer cells. Int J Mol Sci. 2023;24(17):13260.
Zhang JB, Lu ZJ, Yu HZ. Silencing of glycogen synthase kinase 3 significantly inhibits chitin and fatty acid metabolism in Asian citrus psyllid, Diaphorina citri. Int J Mol Sci. 2022;23(17):9654.
Pons BJ, Vignard J, Mirey G. Cytolethal distending toxin subunit B: a review of structure–function relationship. Toxins (Basel). 2019;11(10):595.
Shenker BJ, Boesze-Battaglia K, Scuron MD, Walker LP, Zekavat A, Dlakić M. The toxicity of the Aggregatibacter actinomycetemcomitans cytolethal distending toxin correlates with its phosphatidylinositol-3,4,5-triphosphate phosphatase activity. Cell Microbiol. 2016;18(2):223–43.
Hinze L, Pfirrmann M, Karim S, Degar J, McGuckin C, Vinjamur D, et al. Synthetic lethality of Wnt pathway activation and asparaginase in drug-resistant acute leukemias. Cancer Cell. 2019;35(4):664–76.
Arnould T, Michel S, Renard P. Mitochondria retrograde signaling and the UPRmt: where are we in mammals? Int J Mol Sci. 2015;16(8):18224–18251.
30. Mishra S, Ghanim M. Interactions of Liberibacter species with their psyllid vectors: molecular, biological and behavioural mechanisms. Int J Mol Sci. 2022;23(7):4029.
Kim JH, Creekmore E, Vezina P. Microinjection of CART peptide 55–102 into the nucleus accumbens blocks amphetamine-induced locomotion. Neuropeptides. 2003;37(6):369–73.
Cho BR, Kim WY, Jang JK, Lee JW, Kim JH. Glycogen synthase kinase 3β is a key regulator in the inhibitory effects of accumbal cocaine- and amphetamine-regulated transcript peptide 55–102 on amphetamine-induced locomotor activity. Int J Mol Sci. 2022;23(24):15633.
Kim WY, Jang JK, Lee JW, Jang H, Kim JH. Decrease of GSK3β phosphorylation in the rat nucleus accumbens core enhances cocaine-induced hyper-locomotor activity. J Neurochem. 2013;125(5):642–8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Lingaraj Anawal, Sanjay Havaragi, Chandrasekhar V. M.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
